Skip to main content

Psoriatic arthritis

exhibitor.floor.ACR
Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…
RT @synovialjoints: As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here

Dr. Antoni Chan synovialjoints

1 month ago
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow
PSA2L.jpg
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as for RA…
RT @synovialjoints: In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by Mc

Dr. Antoni Chan synovialjoints

1 month ago
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
RT @doctorRBC: Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44%

Robert B Chao, MD doctorRBC

1 month ago
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
RT @RichardPAConway: Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX

Richard Conway RichardPAConway

1 month ago
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
RT @KDAO2011: Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F

TheDaoIndex KDAO2011

1 month ago
Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU
×